Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | Therapeutic potential of IdeS in hemophilia A with inhibitors

Melissa Bou Jaoudeh • 11 Jul 2022
ISTH 2022
Hemophilia IdeS

Melissa Bou Jaoudeh, PhD, Sorbonne University, Paris, France, comments on the therapeutic potential of IdeS for the treatment of patients with hemophilia A with inhibitors, highlighting the results of an in vivo experiment using a humanized mouse model. The study showed that IdeS led to anti-factor VIII antibody elimination as well as recovery of factor VIII activity. In addition, subsequent injection of factor VIII led to a decrease in blood loss in a tail-clip bleeding model. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Melissa Bou Jaoudeh

1:36
Unmet needs in hemophilia: guidelines for emicizumab & better therapeutics for hemophilia A
Melissa Bou Jaoudeh • 11 Jul 2022
2:27
The impact of hemophilia inhibitors on patient outcomes
Melissa Bou Jaoudeh • 11 Jul 2022

Related Videos

1:08
The current landscape of hemophilia treatment: an update from ASH 2023
Glaivy Batsuli • 10 Dec 2023
1:18
Unmet needs in hemophilia treatment
Glaivy Batsuli • 10 Dec 2023
1:11
Improving outcomes for hemophilia patients through the implementation of gene therapies
Evelien Krumb • 12 Dec 2023
1:27
The impact of emicizumab on the hemophilia treatment landscape
Glaivy Batsuli • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals